Post by
Sosak1 on Jun 21, 2022 8:13am
Dr. Arkady Mandel said
Based on the strength of the clinical data collected and the consistently high safety and efficacy profile of Theralase(TM)'s PDT, I am confident that TLD-1433-based therapy has the potential to become the next gold-standard in the treatment of BCG-Unresponsive patients."
Comment by
Legit62 on Jun 21, 2022 8:43am
I would also think we may get some new data before AGM, Like SF said, all pertinant info has to be made public prior to any release to shareholders, so we may see something very positive next week IMO
Comment by
chry200030 on Jun 21, 2022 9:02am
WOW. excellent. We should rock and rol today.!
Comment by
StevenBirch on Jun 21, 2022 9:26am
Looks like have found their stride again with a surprise news release. We already knew this but I liked these comments from Dr. Kulkarni, "a difficult patient population to treat" and "many also failed other investigational therapies prior to being treated with Theralase's PDT". Looking forward to the next few weeks/months.
Comment by
ScienceFirst on Jun 21, 2022 3:45pm
CancerSlayer ... For the Ph. 1b, you have all this detail in the latest paper published. See the link in this morning news.
Comment by
BlueFranky on Jun 21, 2022 3:58pm
Excellent post Slayer - thank you!
Comment by
99942Apophis on Jun 22, 2022 7:16am
Thanks CancerSlayer your medical education clears many of my questions and my ignorance in that field, my medical knowledge is from watching the movie Dr. Frankenstein lol.
Comment by
Lesalpes29 on Jun 22, 2022 8:43am
Not much interest for this kind of stock in a bear market maybe? News on BTD and deal with a big pharma will solve ower penny stock status I hope!